PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis

Zhijuan Lin, Xing Chen, Zhifeng Li, Yiming Luo, Zhihong Fang, Bing Xu and Mingzhe Han

PLOS ONE, 2016, vol. 11, issue 8, 1-13

Abstract: Antibodies targeting programmed death 1 (PD-1) help prevent tumor cells from escaping immune-mediated destruction. We conducted this systematic review and meta-analysis to gain insight into the efficacy of PD-1 antibodies for the treatment of melanoma. Five trials involving 2,828 adult patients were included in this meta-analysis. In patients with previously untreated or refractory melanoma, treatment with PD-1 antibodies significantly improved the six-month progression-free survival (PFS) (HR 0.55, 95% CI 0.50–0.60, P

Date: 2016
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160485 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 60485&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0160485

DOI: 10.1371/journal.pone.0160485

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().